These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 23154867)
1. Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation. Carr R; Cataland SR Ann Hematol; 2013 Jun; 92(6):845-6. PubMed ID: 23154867 [No Abstract] [Full Text] [Related]
2. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Fakhouri F; Frémeaux-Bacchi V; Loirat C Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030 [TBL] [Abstract][Full Text] [Related]
3. Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome. Cañigral C; Moscardó F; Castro C; Pajares A; Lancharro A; Solves P; de la Rubia J; Carpio N; Sanz MA Ann Hematol; 2014 Aug; 93(8):1421-2. PubMed ID: 24306089 [No Abstract] [Full Text] [Related]
4. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome. Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055 [TBL] [Abstract][Full Text] [Related]
6. Successful discontinuation of eculizumab therapy in a patient with aHUS. Pu JJ; Sido A Ann Hematol; 2014 Aug; 93(8):1423-5. PubMed ID: 24346709 [No Abstract] [Full Text] [Related]
7. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. Zimmerhackl LB; Hofer J; Cortina G; Mark W; Würzner R; Jungraithmayr TC; Khursigara G; Kliche KO; Radauer W N Engl J Med; 2010 May; 362(18):1746-8. PubMed ID: 20445192 [No Abstract] [Full Text] [Related]
8. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Davin JC; Gracchi V; Bouts A; Groothoff J; Strain L; Goodship T Am J Kidney Dis; 2010 Apr; 55(4):708-11. PubMed ID: 19854549 [TBL] [Abstract][Full Text] [Related]
9. Cryptic activity of atypical hemolytic uremic syndrome and eculizumab treatment. Belingheri M; Possenti I; Tel F; Paglialonga F; Testa S; Salardi S; Ardissino G Pediatrics; 2014 Jun; 133(6):e1769-71. PubMed ID: 24843058 [TBL] [Abstract][Full Text] [Related]
10. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome. Christmann M; Hansen M; Bergmann C; Schwabe D; Brand J; Schneider W Pediatrics; 2014 Jun; 133(6):e1759-63. PubMed ID: 24843059 [TBL] [Abstract][Full Text] [Related]
11. Relapse of Atypical Hemolytic Uremic Syndrome During Pregnancy in a Patient on Eculizumab Maintenance Treatment: A Case Report. Fontana F; Alfano G; Bardhushi E; Ligabue G; Giovanella S; Neri I; Cappelli G Am J Case Rep; 2019 Oct; 20():1460-1465. PubMed ID: 31582717 [TBL] [Abstract][Full Text] [Related]
12. Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation. Tran H; Chaudhuri A; Concepcion W; Grimm PC Pediatr Nephrol; 2014 Mar; 29(3):477-80. PubMed ID: 24221349 [TBL] [Abstract][Full Text] [Related]
13. Hemolytic Uremic Syndrome in Pregnancy and Postpartum. Bruel A; Kavanagh D; Noris M; Delmas Y; Wong EKS; Bresin E; Provôt F; Brocklebank V; Mele C; Remuzzi G; Loirat C; Frémeaux-Bacchi V; Fakhouri F Clin J Am Soc Nephrol; 2017 Aug; 12(8):1237-1247. PubMed ID: 28596415 [TBL] [Abstract][Full Text] [Related]
14. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644 [TBL] [Abstract][Full Text] [Related]
15. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. Westra D; Wetzels JF; Volokhina EB; van den Heuvel LP; van de Kar NC Neth J Med; 2012 Apr; 70(3):121-9. PubMed ID: 22516576 [TBL] [Abstract][Full Text] [Related]
16. Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene. Alobaidi S; AlDabbagh A; Alamoudi A; Almowarey M; Akl A CEN Case Rep; 2019 May; 8(2):139-143. PubMed ID: 30715674 [TBL] [Abstract][Full Text] [Related]